Ann Surg Treat Res.  2021 Feb;100(2):76-85. 10.4174/astr.2021.100.2.76.

Effect of Enhanced Recovery After Surgery program on hospital stay and 90-day readmission after pancreaticoduodenectomy: a single, tertiary center experience in Korea

• Kim DH
• Yoon YS
• Han HS
• Cho JY
• Lee JS
• Lee B

• KMID: 2512503
• DOI: http://doi.org/10.4174/astr.2021.100.2.76

Abstract

Purpose
Despite increasing number of reports on Enhanced Recovery After Surgery program (ERAS) and readmission after pancreaticoduodenectomy (PD) from Western countries, there are very few reports on this topic from Asian countries. This study aimed to evaluate the effects of ERAS on hospital stay and readmission and to identify reasons and risk factors for readmission after PD.
Methods
This retrospective cohort study included 670 patients who underwent open PD from January 2003 to December 2017. The patients were classified into ERAS (n = 352) and non-ERAS (n = 318) groups. Patients’ characteristics, perioperative outcomes, and readmission rates were compared.
Results
There were no significant differences in the postoperative complication rates between the groups. The mean postoperative hospital stay was significantly shorter in the ERAS group (24.5 vs. 18.0 days, P < 0.001), but the 90-day readmission rate was similar in the 2 groups (9.1% vs. 8.5%, P = 0.785). Complications associated with pancreatic fistula (42.4%) were the most common cause for readmission. In the multivariate analysis, diabetes mellitus (odds ratio [OR], 1.84;95% confidence interval [CI], 1.05–3.24; P = 0.034), preoperative non-jaundice (OR, 0.45; 95% CI, 0.25–0.82; P = 0.009) and severe postoperative complications (OR, 4.12; 95% CI, 2.34–7.26; P < 0.001) were identified as risk factors for readmission.
Conclusion
The results confirmed that the ERAS program for PD was beneficial in reducing postoperative stay without increasing readmission risks. To decrease readmission rates, prudent discharge planning and medical support should be considered in patients who experience severe complications.

Keyword

Enhanced Recovery After Surgery; Length of stay; Korea; Pancreaticoduodenectomy; Patient readmission

Figure

• 

  Fig. 1 (A) Temporal change of postoperative hospital stay (PHS) and readmission rate. (B) Comparison of the changes in trends of PHS before and after Enhanced Recovery After Surgery (ERAS).

Reference

1. Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg. 2007; 204:356–364. PMID: 17324768.

2. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000; 232:786–795. PMID: 11088073.

3. Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr. 2010; 29:434–440. PMID: 20116145.

4. Teeuwen PH, Bleichrodt RP, Strik C, Groenewoud JJ, Brinkert W, van Laarhoven CJ, et al. Enhanced recovery after surgery (ERAS) versus conventional postoperative care in colorectal surgery. J Gastrointest Surg. 2010; 14:88–95. PMID: 19779947.

5. Lassen K, Coolsen MM, Slim K, Carli F, de Aguilar-Nascimento JE, Schäfer M, et al. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr. 2012; 31:817–830. PMID: 23079762.

6. Takagi K, Yoshida R, Yagi T, Umeda Y, Nobuoka D, Kuise T, et al. Effect of an enhanced recovery after surgery protocol in pat ients undergoing pancreaticoduodenectomy: a randomized controlled trial. Clin Nutr. 2019; 38:174–181. PMID: 29373148.

7. Pearson SD, Kleefield SF, Soukop JR, Cook EF, Lee TH. Critical pathways intervention to reduce length of hospital stay. Am J Med. 2001; 110:175–180. PMID: 11182102.

8. Porter GA, Pisters PW, Mansyur C, Bisanz A, Reyna K, Stanford P, et al. Cost and utilization impact of a clinical pathway for pat ients undergoing pancreaticoduodenectomy. Ann Surg Oncol. 2000; 7:484–489. PMID: 10947015.

9. Vanounou T, Pratt W, Fischer JE, Vollmer CM Jr, Callery MP. Deviation-based cost modeling: a novel model to evaluate the clinical and economic impact of clinical pathways. J Am Coll Surg. 2007; 204:570–579. PMID: 17382215.

10. Montiel Casado MC, Pardo Sánchez F, Rotellar Sastre F, Martí Cruchaga P, Alvarez Cienfuegos FJ. [Experience of a cephalic pancreatoduodenectomy fast-track program]. Cir Esp. 2010; 87:378–384. Spanish. PMID: 20462572.

11. Brown EG, Yang A, Canter RJ, Bold RJ. Outcomes of pancreaticoduodenectomy: where should we focus our efforts on improving outcomes. JAMA Surg. 2014; 149:694–699. PMID: 24849180.

12. Schneider EB, Hyder O, Wolfgang CL, Hirose K, Choti MA, Makary MA, et al. Patient readmission and mortality after surgery for hepato-pancreatobiliary malignancies. J Am Coll Surg. 2012; 215:607–615. PMID: 22921328.

13. Hicks CW, Tosoian JJ, Craig-Schapiro R, Valero V 3rd, Cameron JL, Eckhauser FE, et al. Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. Am J Surg. 2015; 210:636–642. PMID: 26384793.

14. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017; 161:584–591. PMID: 28040257.

15. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007; 142:761–768. PMID: 17981197.

16. Schneider EB, Hyder O, Wolfgang CL, Dodson RM, Haider AH, Herman JM, et al. Provider versus patient factors impacting hospital length of stay after pancreaticoduodenectomy. Surgery. 2013; 154:152–161. PMID: 23889945.

17. Van Buren G 2nd, Bloomston M, Hughes SJ, Winter J, Behrman SW, Zyromski NJ, et al. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg. 2014; 259:605–612. PMID: 24374513.

18. Grewal SS, McClaine RJ, Schmulewitz N, Alzahrani MA, Hanseman DJ, Sussman JJ, et al. Factors associated with recidivism following pancreaticoduodenectomy. HPB (Oxford). 2011; 13:869–875. PMID: 22081922.

19. Ahmad SA, Edwards MJ, Sutton JM, Grewal SS, Hanseman DJ, Maithel SK, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1,302 patients. Ann Surg. 2012; 256:529–537. PMID: 22868373.

20. Yermilov I, Bentrem D, Sekeris E, Jain S, Maggard MA, Ko CY, et al. Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol. 2009; 16:554–561. PMID: 19002528.

21. Valero V 3rd, Grimm JC, Kilic A, Lewis RL, Tosoian JJ, He J, et al. A novel risk scoring system reliably predicts readmission after pancreatectomy. J Am Coll Surg. 2015; 220:701–713. PMID: 25797757.

22. Fisher AV, Fernandes-Taylor S, Campbell-Flohr SA, Clarkson SJ, Winslow ER, Abbott DE, et al. 30-day readmission after pancreatic resection: a systematic review of the literature and meta-analysis. Ann Surg. 2017; 266:242–250. PMID: 28323675.

23. Reddy DM, Townsend CM Jr, Kuo YF, Freeman JL, Goodwin JS, Riall TS. Readmission after pancreatectomy for pancreatic cancer in Medicare patients. J Gastrointest Surg. 2009; 13:1963–1974. PMID: 19760307.

24. Fong ZV, Ferrone CR, Thayer SP, Wargo JA, Sahora K, Seefeld KJ, et al. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014; 18:137–144. PMID: 24002770.

25. Hwang DW, Kim HJ, Lee JH, Song KB, Kim MH, Lee SK, et al. Effect of Enhanced Recovery After Surgery program on pancreaticoduodenectomy: a randomized controlled trial. J Hepatobiliary Pancreat Sci. 2019; 26:360–369. PMID: 31152686.